Hong Kong Widens Vaccine Access to Residents Ages 16 And Up
(Bloomberg) — Hong Kong expanded eligibility for Covid-19 vaccines to all residents aged 16 and older in the government’s latest attempt to boost a low inoculation rate by making the shots widely accessible.
Residents aged 16 and above will be allowed to receive BioNTech SE vaccines, while those older than 18 will also be able to opt for shots made by China’s Sinovac Biotech Ltd., Secretary for Civil Service Patrick Nip said at a briefing on Thursday. Bookings for the expanded group will start on April 23, Nip said, and 16 and 17-year-olds will need parental consent forms to be vaccinated.
BioNTech vaccinations will only last until the end of September because of supply constraints, Nip said, and appointments for the first dose must be made by August. He urged citizens to get inoculated as soon as possible.
No third vaccine is expected in the city this year, said Food and Health Secretary Sophia Chan.
The expansion means that Hong Kong’s entire adult population will now be eligible to receive vaccines, making it one of the first places globally to offer eligibility to all adults.
“We have the capacity to expand the coverage of the vaccination scheme,” Nip said. “It’s the appropriate time to introduce this arrangement.”
About 951,000 vaccine doses had been administered to the Hong Kong public as of Wednesday, according to Bloomberg’s Covid-19 Vaccine Tracker — with at least one dose given to just 8.4% of the population, compared to 19.8% in Singapore, another major financial center.
The expansion comes days after the city outlined “vaccine bubbles” that would impose fewer social curbs on vaccinated people. Chief Executive Carrie Lam has also said the government was planning to only allow those who’ve had Covid-19 shots to fly from the city to Singapore once both governments finalize a travel bubble.
Hong Kong has been expanding vaccine access rapidly since its rollout started in late February, as few among priority groups came forward in earlier stages of the campaign. Healthy adults aged 30 and up, domestic helpers and students aged 16 and above who study at overseas institutions became eligible in March.
The city is currently administering vaccines made by Sinovac and Mainz, Germany-based BioNTech, after the latter was temporarily halted last month following packaging defects found in some vials. The BioNTech program was resumed after authorities concluded that the defects didn’t pose a safety risk.
Support quality journalism in China. Subscribe to Caixin Global starting at $0.99.
Follow the Chinese markets in real time with Caixin Global’s new stock database.
- MOST POPULAR